GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Gland Pharma Ltd

Gland Pharma Q2 FY27 Revenue up 23% YoY to ₹18,336 Mn; PAT up 58% YoY

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 06 Nov 2026, 04:52 PM IST  ·  BSE ID: f8ad1beb-5537-4b31-8341-04ca814c97c4
View Original BSE Filing (PDF)
💡
In Simple Terms
Gland Pharma reported strong quarterly earnings, with revenue rising 23% and profit increasing 58% compared to last year.
🤖 AI Summary
  • Gland Pharma's Q2 FY27 revenue from operations increased 23% year-on-year to ₹18,336 million.
  • Profit After Tax (PAT) for Q2 FY27 grew 58% year-on-year to ₹2,908 million.
  • The Contract Development and Manufacturing Organization (CDMO) business grew 31% year-on-year.
  • USA market revenue for Q2 FY27 was ₹11,795 million, marking a 42% year-on-year increase.
  • The company launched 4 molecules in the USA and filed 11 ANDAs in Q2 FY27.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
18,336 ₹ Mn
23%
PAT (Q2 FY27)
2,908 ₹ Mn
58%
Adj. EBITDA (Q2 FY27)
5,030 ₹ Mn
50%
CDMO business growth (Q2 FY27)
8,227 ₹ Mn
31%
USA Market Revenue (Q2 FY27)
11,795 ₹ Mn
42%
R&D investments (Q2 FY27)
1,077 ₹ Mn
🏢 How This Affects the Company
📈
Business Impact
The company's core businesses, CDMO and Critical Injectables, demonstrated substantial year-on-year growth of 31% and 18% respectively, expanding its market presence. New product launches and pipeline additions in the USA reinforce future revenue streams.
💰
Financial Impact
Gland Pharma improved its Profit After Tax (PAT) margin to 16% in Q2 FY27 from 12% in Q2 FY26. Adj. EBITDA margin also increased to 27% from 23% year-on-year, indicating enhanced operational profitability.
⚙️
Operational Impact
Investments in R&D, totaling ₹1,077 million in Q2 FY27, are directed towards complex product development and new filings. Two facilities audited by USFDA, with one concluding with four procedural observations, reflect ongoing compliance efforts.
⚠️
Risk Impact
The USFDA procedural observations at the Dundigal facility, while not critical, highlight the ongoing need for rigorous compliance and could require operational adjustments.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the 58% year-on-year increase in PAT to ₹2,908 million in Q2 FY27. This reflects overall profitability.
🔍
Management Signal
Management's statement emphasizes continued investments in manufacturing capabilities, innovation, and capacity expansion to capitalize on global outsourcing opportunities.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor USA market growth sustainability and overall revenue.
Updates on Dundigal USFDA observations — confirm resolution and compliance status.
Progress on co-development partnerships — track commercialization timelines for FY29.
LOW RISK The filing indicates strong financial performance and strategic initiatives, with minor procedural USFDA observations identified.
💡 Investor Takeaway
Gland Pharma reported Q2 FY27 revenue from operations of ₹18,336 million, up 23% year-on-year, and PAT of ₹2,908 million, up 58% year-on-year. The CDMO business grew 31% year-on-year, while the USA market revenue increased 42% year-on-year to ₹11,795 million.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 Revenue from operations grew 23% year-on-year to ₹18,336 million.
  • Profit After Tax (PAT) increased 58% year-on-year to ₹2,908 million in Q2 FY27.

⚠️ Concerns

  • Revenue from Canada, Australia, and New Zealand decreased 18% year-on-year to ₹400 million in Q2 FY27.
  • Revenue from India declined 42% year-on-year to ₹387 million in Q2 FY27.
📅 Company Track Record
In Q4 FY26, Gland Pharma reported revenue up 22% YoY to ₹17,428 Million and adjusted PAT up 97%. The company recommended a final dividend of Rs. 20 per share for FY26. This Q2 FY27 filing continues a trend of double-digit revenue and profit growth.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Gland Pharma's revenue from operations in Q2 FY27?
Gland Pharma's revenue from operations in Q2 FY27 was ₹18,336 million, a 23% increase compared to ₹14,869 million in Q2 FY26.
How much did Gland Pharma's Profit After Tax (PAT) grow in Q2 FY27?
Gland Pharma's Profit After Tax (PAT) grew 58% year-on-year to ₹2,908 million in Q2 FY27, up from ₹1,837 million in Q2 FY26.
What was the growth rate of Gland Pharma's CDMO business in Q2 FY27?
Gland Pharma's CDMO business grew 31% year-on-year in Q2 FY27, contributing ₹8,227 million to revenues.
What was the revenue from the USA market for Gland Pharma in Q2 FY27?
Revenue from the USA market for Gland Pharma in Q2 FY27 was ₹11,795 million, reflecting a 42% year-on-year growth.
What were Gland Pharma's R&D expenses in Q2 FY27?
Gland Pharma's R&D expenses in Q2 FY27 stood at ₹1,077 million, representing 6% of consolidated revenue.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.